share_log

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Jordt Raymond M

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Jordt Raymond M

Altimmune | 4：持股變動聲明-高管 Jordt Raymond M
美股sec公告 ·  08/02 05:46
牛牛AI助理已提取核心訊息
Raymond M. Jordt, the Chief Business Officer of Altimmune, Inc., completed a purchase of 917 shares of common stock on July 31, 2024. The transaction was carried out directly with the shares valued at $5.41 each. Following this acquisition, Jordt's total direct holdings in the company increased to 14,660 shares. The transaction is part of a grant, award, or other acquisition, as per the transaction code description provided.
Raymond M. Jordt, the Chief Business Officer of Altimmune, Inc., completed a purchase of 917 shares of common stock on July 31, 2024. The transaction was carried out directly with the shares valued at $5.41 each. Following this acquisition, Jordt's total direct holdings in the company increased to 14,660 shares. The transaction is part of a grant, award, or other acquisition, as per the transaction code description provided.
業務主管Raymond M. Jordt於2024年7月31日直接購買了917股普通股。每股價值5.41美元。此次收購後，Jordt在公司的直接持股總數增至14,660股。該交易是根據交易代碼說明提供的授予、獎勵或其他獲得的一部分。
業務主管Raymond M. Jordt於2024年7月31日直接購買了917股普通股。每股價值5.41美元。此次收購後，Jordt在公司的直接持股總數增至14,660股。該交易是根據交易代碼說明提供的授予、獎勵或其他獲得的一部分。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。